Direct Switch from Latuda 20mg to Rexulti for Akathisia
Yes, you can switch directly from Latuda 20mg to Rexulti (brexpiprazole) for akathisia, using a gradual cross-titration approach rather than an abrupt switch. This strategy addresses the akathisia while maintaining antipsychotic coverage and minimizing withdrawal or rebound symptoms.
Rationale for Switching
Akathisia is a well-documented adverse effect of lurasidone (Latuda), with FDA labeling showing akathisia rates of 5.6% at 20mg/day 11. The evidence demonstrates that:
- Lurasidone has a higher akathisia burden compared to brexpiprazole. Meta-analysis data shows lurasidone has an akathisia incidence of 12.7% overall, while brexpiprazole shows 10.0% 2
- Brexpiprazole may be better tolerated in patients who have failed switches to other dopamine partial agonists, with retrospective data suggesting safer switching profiles compared to aripiprazole 3
- Both medications are second-generation antipsychotics but have different pharmacodynamic profiles, making this a reasonable switch per guideline recommendations 4
Switching Strategy
Use gradual cross-titration as recommended by the 2025 INTEGRATE guidelines 4:
- Start brexpiprazole at 1mg/day while continuing Latuda 20mg
- After 3-4 days, increase brexpiprazole to 2mg/day
- Simultaneously begin tapering Latuda by 50% (to 10mg/day)
- After another 3-4 days, increase brexpiprazole to target dose (2-4mg/day) and discontinue Latuda
- Total cross-titration period: 7-10 days
This gradual approach is informed by:
- The half-life and receptor profiles of each medication 4
- Lurasidone's relatively short half-life requiring food administration
- Brexpiprazole's partial dopamine agonist properties requiring gradual introduction
Important Caveats
Monitor for akathisia persistence: While brexpiprazole has a lower akathisia rate than lurasidone in meta-analyses 2, it still carries akathisia risk (RR 1.72 vs placebo) 5. The 2mg dose of brexpiprazole shows less akathisia risk than 4mg 5.
Consider adjunctive management during transition:
- Beta-blockers (propranolol 30-90mg/day) are first-line adjuncts for akathisia 6
- Benzodiazepines can provide temporary relief during the cross-titration
- These can be tapered once the switch is complete and akathisia resolves
Special considerations:
- If you're treating schizophrenia with treatment-resistant features, switching success rates may be lower 3
- Brexpiprazole is FDA-approved for schizophrenia and MDD augmentation, so ensure the indication aligns
- Both medications require different dosing considerations (Latuda with food ≥350 calories; brexpiprazole without food restrictions)
Expected Outcomes
Akathisia should improve within 1-2 weeks of completing the switch. If akathisia persists at the same severity after switching to brexpiprazole 2mg/day, this suggests either:
- The akathisia may be related to class effects rather than medication-specific
- Consider dose reduction of brexpiprazole or addition of adjunctive treatments 6
- Re-evaluate if this represents tardive akathisia rather than acute medication-induced akathisia
Do not switch abruptly - the guideline explicitly recommends against abrupt switches, particularly when moving between different pharmacodynamic profiles 4. The gradual cross-titration minimizes risk of symptom exacerbation or withdrawal effects.